Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Similar articles for PubMed (Select 21623760)

1.

Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.

Loh ML.

Br J Haematol. 2011 Mar;152(6):677-87. doi: 10.1111/j.1365-2141.2010.08525.x. Review.

PMID:
21623760
2.

Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.

Loh ML.

Hematology Am Soc Hematol Educ Program. 2010;2010:357-62. doi: 10.1182/asheducation-2010.1.357. Review.

3.

Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.

Chang TY, Dvorak CC, Loh ML.

Blood. 2014 Oct 16;124(16):2487-97. doi: 10.1182/blood-2014-03-300319. Epub 2014 Aug 27. Review.

PMID:
25163700
4.

Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy.

Loh ML, Mullighan CG.

Clin Cancer Res. 2012 May 15;18(10):2754-67. doi: 10.1158/1078-0432.CCR-11-1936. Review.

5.

Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.

Koike K, Matsuda K.

Br J Haematol. 2008 May;141(5):567-75. doi: 10.1111/j.1365-2141.2008.07104.x. Epub 2008 Apr 13. Review.

PMID:
18422786
6.

Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.

Niemeyer CM, Kratz CP.

Br J Haematol. 2008 Mar;140(6):610-24. doi: 10.1111/j.1365-2141.2007.06958.x. Review.

PMID:
18302710
7.

Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Yoshida N, Doisaki S, Kojima S.

Paediatr Drugs. 2012 Jun 1;14(3):157-63. doi: 10.2165/11631360-000000000-00000. Review.

PMID:
22480363
8.

Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.

Yoshimi A, Kojima S, Hirano N.

Paediatr Drugs. 2010;12(1):11-21. doi: 10.2165/11316200-000000000-00000. Review.

PMID:
20034338
9.

Juvenile myelomonocytic leukemia.

Proytcheva M.

Semin Diagn Pathol. 2011 Nov;28(4):298-303. Review.

PMID:
22195407
10.

Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.

Bunda S, Kang MW, Sybingco SS, Weng J, Favre H, Shin DH, Irwin MS, Loh ML, Ohh M.

Cancer Res. 2013 Apr 15;73(8):2540-50. doi: 10.1158/0008-5472.CAN-12-3425. Epub 2013 Feb 11.

11.

Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group.

Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, Sanders J, Neudorf S, Gold S, Lange BJ.

J Clin Oncol. 2002 Jan 15;20(2):434-40.

PMID:
11786571
12.

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.

Pérez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cavé H.

Br J Haematol. 2010 Dec;151(5):460-8. doi: 10.1111/j.1365-2141.2010.08393.x. Epub 2010 Oct 19.

PMID:
20955399
13.

[Juvenile myelomonocytic leukemias].

Lachenaud J, Strullu M, Baruchel A, Cavé H.

Bull Cancer. 2014 Mar;101(3):302-13. doi: 10.1684/bdc.2014.1908. Review. French.

PMID:
24691193
14.

Clinical characteristics of 15 children with juvenile myelomonocytic leukaemia who developed blast crisis: MDS Committee of Japanese Society of Paediatric Haematology/Oncology.

Honda Y, Tsuchida M, Zaike Y, Masunaga A, Yoshimi A, Kojima S, Ito M, Kikuchi A, Nakahata T, Manabe A.

Br J Haematol. 2014 Jun;165(5):682-7. doi: 10.1111/bjh.12796. Epub 2014 Mar 4.

PMID:
24588411
15.

Juvenile myelomonocytic leukemia.

Satwani P, Kahn J, Dvorak CC.

Pediatr Clin North Am. 2015 Feb;62(1):95-106. doi: 10.1016/j.pcl.2014.09.003. Review.

PMID:
25435114
16.

Myelodysplastic/myeloproliferative neoplasms.

Hyjek E, Vardiman JW.

Semin Diagn Pathol. 2011 Nov;28(4):283-97. Review.

PMID:
22195406
17.

How I treat juvenile myelomonocytic leukemia.

Locatelli F, Niemeyer CM.

Blood. 2015 Feb 12;125(7):1083-90. doi: 10.1182/blood-2014-08-550483. Epub 2015 Jan 6. Review.

PMID:
25564399
18.

[Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].

Manabe A.

Rinsho Ketsueki. 2012 Aug;53(8):729-33. Review. Japanese. No abstract available.

PMID:
22975811
19.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

20.

Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.

Olk-Batz C, Poetsch AR, Nöllke P, Claus R, Zucknick M, Sandrock I, Witte T, Strahm B, Hasle H, Zecca M, Stary J, Bergstraesser E, De Moerloose B, Trebo M, van den Heuvel-Eibrink MM, Wojcik D, Locatelli F, Plass C, Niemeyer CM, Flotho C; European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS).

Blood. 2011 May 5;117(18):4871-80. doi: 10.1182/blood-2010-08-298968. Epub 2011 Mar 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk